TG Therapeutics (TGTX) Weak On High Volume

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified TG Therapeutics ( TGTX) as a weak on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified TG Therapeutics as such a stock due to the following factors:

  • TGTX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $3.8 million.
  • TGTX has traded 50,493 shares today.
  • TGTX is trading at 3.80 times the normal volume for the stock at this time of day.
  • TGTX is trading at a new low 5.05% below yesterday's close.

'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in TGTX with the Ticky from Trade-Ideas. See the FREE profile for TGTX NOW at Trade-Ideas

More details on TGTX:

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of various pharmaceutical products for the treatment of cancer and other underserved therapeutic needs.

The average volume for TG Therapeutics has been 237,400 shares per day over the past 30 days. TG has a market cap of $228.8 million and is part of the health care sector and drugs industry. The stock has a beta of 1.86 and a short float of 7.2% with 5.86 days to cover.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

SAP Shares Leap After Cloud Business Prompts Full-Year Guidance Upgrade

SAP Shares Leap After Cloud Business Prompts Full-Year Guidance Upgrade

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%